Biotechs buck a sluggish IPO market, but investors should tread warily

Biotech accounted for 11 of 16 U.S. IPOs since the start of August, bringing the year’s biotech IPO count to 26—more than double 2025’s tally and the highest since 2021. But historical outcomes are weak: among 75 biotech IPOs from 2020, only 16% have positive returns and 44% have fallen at least 90%; an equal-weight investment would be down more than 25%. The article notes a 35% gain for the iShares Biotechnology ETF in 2026 through Tuesday’s close, while emphasizing that company-level clinical and commercial risks make IPO selection difficult.

Analysis

The key market signal is not that biotech IPOs are “back,” but that financing has reopened selectively for companies with discrete clinical catalysts. That can extend runway for private and newly public developers, yet it does not establish durable demand: IPO counts can rise while the marginal issuer’s quality and post-listing liquidity deteriorate. The 2020 cohort is a warning against treating sector inflows as a reliable proxy for eventual equity value.

Second-order beneficiaries are service and software vendors if newly funded companies convert proceeds into trial activity. IQVIA and Veeva Systems have more diversified exposure than any single drug developer; however, vendor revenue may lag fundraising, and the benefit depends on actual trial starts and customer budgets. The expanded IQVIA–Veeva relationship could broaden access while also sharpening competition for life-sciences workflows. Danaher is a less direct way to express the theme. Royalty Pharma’s commitment to Revolution Medicines illustrates an alternative financing channel, but milestone-linked capital is not a blanket backstop for weaker issuers.

Over days, IPO enthusiasm and the 35% year-to-date IBB move argue against chasing the broad biotech trade. Over 1–3 months, Veeva’s Nov. 5 investor day is a catalyst for evidence on AI monetization and customer demand; over 6–18 months, trial starts and vendor bookings will test whether the funding window translates into recurring spend. The contrarian risk is that investors extrapolate a few clinical winners and M&A activity to a broad IPO cohort despite long development timelines and binary trial outcomes.

Key Decisions for Investors

• Prefer a staged long in VEEV over a broad basket of newly listed clinical-stage biotechs; add only if the Nov. 5 investor day supports measurable customer adoption or monetization, and reduce if guidance or bookings fail to confirm the thesis. No valuation data is provided, so avoid sizing this as a high-conviction standalone trade.
• Track IQV and DHR as diversified picks-and-shovels beneficiaries, but require evidence of trial-volume or order growth before adding exposure. The thesis is falsified if biotech financing remains active while customer bookings and trial starts weaken over the next several quarters.
• Do not infer IPO quality from deal volume or extrapolate RVMD’s outcome to the cohort. For any new issue, verify cash runway, lead-asset phase, pipeline breadth, management record, and dilution risk; treat weak runway or a failed pivotal endpoint as potential near-total equity-loss risks.
• Near term, avoid chasing IBB after its sharp advance. Reassess after the IPO calendar and funding data show whether demand is broadening beyond a small number of issuers; a reversal in biotech financing or a deterioration in clinical readouts would invalidate the sector-tailwind thesis.